KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Inventory (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Inventory data on record, last reported at $417.0 million in Q4 2025.

  • For Q4 2025, Inventory fell 13.21% year-over-year to $417.0 million; the TTM value through Dec 2025 reached $417.0 million, down 13.21%, while the annual FY2025 figure was $417.0 million, 13.21% down from the prior year.
  • Inventory reached $417.0 million in Q4 2025 per JAZZ's latest filing, down from $483.1 million in the prior quarter.
  • Across five years, Inventory topped out at $1.3 billion in Q2 2021 and bottomed at $115.5 million in Q1 2021.
  • Average Inventory over 5 years is $672.2 million, with a median of $604.4 million recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 1252.22% in 2021, then tumbled 36.01% in 2022.
  • A 5-year view of Inventory shows it stood at $1.1 billion in 2021, then plummeted by 33.43% to $714.1 million in 2022, then dropped by 16.39% to $597.0 million in 2023, then fell by 19.53% to $480.4 million in 2024, then fell by 13.21% to $417.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $417.0 million in Q4 2025, $483.1 million in Q3 2025, and $505.0 million in Q2 2025.